alosetron has been researched along with Diarrhea in 39 studies
alosetron : A pyrido[4,3-b]indole compound having a 5-methyl-1H-imidazol-4-ylmethyl group at the 2-position.
Diarrhea: An increased liquidity or decreased consistency of FECES, such as running stool. Fecal consistency is related to the ratio of water-holding capacity of insoluble solids to total water, rather than the amount of water present. Diarrhea is not hyperdefecation or increased fecal weight.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Alosetron is indicated for women with chronic, severe diarrhea-predominant IBS (d-IBS) who have not responded adequately to conventional therapy." | 9.12 | A randomized, double-blind, placebo-controlled study to assess efficacy and safety of 0.5 mg and 1 mg alosetron in women with severe diarrhea-predominant IBS. ( Ameen, V; Carter, EG; Gordon, SH; Heath, AT; Krause, R; Perschy, T; West, M, 2007) |
| "Alosetron 1 mg twice daily provided adequate relief of IBS pain and discomfort, and improved stool consistency in men with diarrhea-predominant IBS." | 9.11 | A dose-ranging, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS. ( Ameen, VZ; Carter, EG; Chang, L; Dukes, GE; Mayer, EA; McSorley, DJ, 2005) |
| "Long-term use of alosetron is effective and well-tolerated in women with chronic, diarrhea-predominant IBS, including those with more frequent urgency." | 9.11 | Long-term safety and efficacy of alosetron in women with severe diarrhea-predominant irritable bowel syndrome. ( Ameen, VZ; Carter, EG; Chey, WD; Chey, WY; Dukes, GE; Heath, AT; Northcutt, A, 2004) |
| "The aim of this study was to assess the effect of alosetron on bowel urgency and irritable bowel syndrome (IBS) global improvement in diarrhea-predominant IBS (D-IBS)." | 9.11 | Effect of alosetron on bowel urgency and global symptoms in women with severe, diarrhea-predominant irritable bowel syndrome: analysis of two controlled trials. ( Ameen, VZ; Carter, EG; Gordon, SL; Heath, AT; Lembo, AJ; Olden, KW, 2004) |
| "The efficacy and tolerability of alosetron in women with diarrhea-predominant irritable bowel syndrome (IBS) have been established in double-blind, placebo-controlled trials." | 9.10 | Patient satisfaction with alosetron for the treatment of women with diarrhea-predominant irritable bowel syndrome. ( Bagby, B; Bobbitt, W; Carter, E; Dahdul, A; DeCastro, E; Decker, C; DeGarmo, RG; Gringeri, L; Jhingran, P; Johanson, J; Levinson, L; Markowitz, M; Mula, G; Olden, K; Poleynard, G; Stoltz, RR; Truesdale, R; Young, D, 2002) |
| "The aim of this study was to assess the impact of alosetron, a treatment recently approved in the United States for irritable bowel syndrome in diarrhea-predominant female patients, on health-related quality of life." | 9.09 | Alosetron improves quality of life in women with diarrhea-predominant irritable bowel syndrome. ( Hahn, B; Kong, S; Lacey, L; Mangel, AW; McSorley, D; Northcutt, AR; Watson, ME, 2001) |
| "Alosetron hydrochloride, 1 mg twice daily for 12 weeks, is effective in relieving pain and some bowel-related symptoms in diarrhea-predominant female patients with IBS." | 9.09 | A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome. ( Camilleri, M; Chey, WY; Dukes, GE; Heath, A; Mangel, AM; Mayer, EA; McSorley, D; Northcutt, AR, 2001) |
| " Direct comparison of primary endpoint results from the alosetron, rifaximin, and eluxadoline pivotal trials is not possible; however, general estimates of efficacy can be made, and these demonstrate similar and significantly greater responses to 'adequate relief' and a composite endpoint of abdominal pain/stool form for each agent compared to placebo." | 8.93 | Rifaximin and eluxadoline - newly approved treatments for diarrhea-predominant irritable bowel syndrome: what is their role in clinical practice alongside alosetron? ( Cash, BD; Earnest, DL; Lacy, BE; Rao, T, 2016) |
| " The goal of this review is to discern IBS treatment gaps and identify opportunities for improving its management in the primary care setting, as well as describe the most current clinical experience with alosetron, a targeted treatment for severe diarrhea-predominant IBS (IBS-D) in women." | 8.87 | Alosetron for severe diarrhea-predominant irritable bowel syndrome: improving patient outcomes. ( Bleser, S, 2011) |
| "Ischemic colitis and serious complications of constipation have been reported in association with the use of alosetron, which is approved for women with severe diarrhea-predominant IBS who have failed conventional therapies." | 8.83 | Incidence of ischemic colitis and serious complications of constipation among patients using alosetron: systematic review of clinical trials and post-marketing surveillance data. ( Chang, L; Chey, WD; Harris, L; Olden, K; Schoenfeld, P; Surawicz, C, 2006) |
| " The present study examines the binding profile of platelet SERT in healthy volunteers as well as in patients with diarrhea-predominant irritable bowel syndrome (D-IBS), both before and after treatment with the 5-HT(3) receptor antagonist alosetron." | 7.72 | Platelet serotonin transporter in patients with diarrhea-predominant irritable bowel syndrome both before and after treatment with alosetron. ( Baroni, S; Bellini, M; Betti, L; Blandizzi, C; Colucci, R; Costa, F; Del Tacca, M; Giannaccini, G; Marazziti, D; Marchi, S; Mumolo, MG; Rappelli, L; Stasi, C, 2003) |
| "Alosetron-treated patients showed improvements in bowel functions compared to placebo-treated patients." | 6.70 | Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome. ( Bagby, B; Carter, E; Decker, C; Gordon, S; Jhingran, P; Lembo, T; Wright, RA, 2001) |
| "Irritable bowel syndrome is categorized into one of three main categories: IBS with diarrhea, IBS with constipation, and IBS with mixed bowel habits." | 6.53 | Emerging treatments in neurogastroenterology: eluxadoline - a new therapeutic option for diarrhea-predominant IBS. ( Lacy, BE, 2016) |
| "Alosetron treatment improved HRQOL scores for all domains (p < ." | 5.51 | Alosetron versus traditional pharmacotherapy in clinical practice: effects on resource use, health-related quality of life, safety and symptom improvement in women with severe diarrhea-predominant irritable bowel syndrome. ( Chey, WD; Chuang, E; Earnest, DL; Olden, KW; Paul Nicandro, J; Shringarpure, R, 2019) |
| " Initial use was widespread, but infrequent serious adverse events of ischemic colitis and severe constipation-related complications prompted alosetron's voluntary withdrawal from the US market in November 2000." | 5.36 | Alosetron for severe diarrhea-predominant irritable bowel syndrome: safety and efficacy in perspective. ( Lewis, JH, 2010) |
| "Alosetron is indicated for women with chronic, severe diarrhea-predominant IBS (d-IBS) who have not responded adequately to conventional therapy." | 5.12 | A randomized, double-blind, placebo-controlled study to assess efficacy and safety of 0.5 mg and 1 mg alosetron in women with severe diarrhea-predominant IBS. ( Ameen, V; Carter, EG; Gordon, SH; Heath, AT; Krause, R; Perschy, T; West, M, 2007) |
| "Long-term use of alosetron is effective and well-tolerated in women with chronic, diarrhea-predominant IBS, including those with more frequent urgency." | 5.11 | Long-term safety and efficacy of alosetron in women with severe diarrhea-predominant irritable bowel syndrome. ( Ameen, VZ; Carter, EG; Chey, WD; Chey, WY; Dukes, GE; Heath, AT; Northcutt, A, 2004) |
| "Alosetron 1 mg twice daily provided adequate relief of IBS pain and discomfort, and improved stool consistency in men with diarrhea-predominant IBS." | 5.11 | A dose-ranging, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS. ( Ameen, VZ; Carter, EG; Chang, L; Dukes, GE; Mayer, EA; McSorley, DJ, 2005) |
| "The aim of this study was to assess the effect of alosetron on bowel urgency and irritable bowel syndrome (IBS) global improvement in diarrhea-predominant IBS (D-IBS)." | 5.11 | Effect of alosetron on bowel urgency and global symptoms in women with severe, diarrhea-predominant irritable bowel syndrome: analysis of two controlled trials. ( Ameen, VZ; Carter, EG; Gordon, SL; Heath, AT; Lembo, AJ; Olden, KW, 2004) |
| "The efficacy and tolerability of alosetron in women with diarrhea-predominant irritable bowel syndrome (IBS) have been established in double-blind, placebo-controlled trials." | 5.10 | Patient satisfaction with alosetron for the treatment of women with diarrhea-predominant irritable bowel syndrome. ( Bagby, B; Bobbitt, W; Carter, E; Dahdul, A; DeCastro, E; Decker, C; DeGarmo, RG; Gringeri, L; Jhingran, P; Johanson, J; Levinson, L; Markowitz, M; Mula, G; Olden, K; Poleynard, G; Stoltz, RR; Truesdale, R; Young, D, 2002) |
| "The aim of this study was to assess the impact of alosetron, a treatment recently approved in the United States for irritable bowel syndrome in diarrhea-predominant female patients, on health-related quality of life." | 5.09 | Alosetron improves quality of life in women with diarrhea-predominant irritable bowel syndrome. ( Hahn, B; Kong, S; Lacey, L; Mangel, AW; McSorley, D; Northcutt, AR; Watson, ME, 2001) |
| "In female irritable bowel syndrome patients with predominant diarrhoea or alternating constipation and diarrhoea, alosetron is effective in treatment of abdominal pain and discomfort and bowel-related symptoms." | 5.09 | Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist. ( Camilleri, M; Drossman, DA; Dukes, GE; Heath, A; Kong, S; Mangel, AW; Mayer, EA; McSorley, D; Northcutt, AR, 1999) |
| "Alosetron hydrochloride, 1 mg twice daily for 12 weeks, is effective in relieving pain and some bowel-related symptoms in diarrhea-predominant female patients with IBS." | 5.09 | A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome. ( Camilleri, M; Chey, WY; Dukes, GE; Heath, A; Mangel, AM; Mayer, EA; McSorley, D; Northcutt, AR, 2001) |
| " Direct comparison of primary endpoint results from the alosetron, rifaximin, and eluxadoline pivotal trials is not possible; however, general estimates of efficacy can be made, and these demonstrate similar and significantly greater responses to 'adequate relief' and a composite endpoint of abdominal pain/stool form for each agent compared to placebo." | 4.93 | Rifaximin and eluxadoline - newly approved treatments for diarrhea-predominant irritable bowel syndrome: what is their role in clinical practice alongside alosetron? ( Cash, BD; Earnest, DL; Lacy, BE; Rao, T, 2016) |
| "In irritable bowel syndrome with diarrhea, tricyclic antidepressants and alosetron are associated with a significant number needed to harm compared with rifaximin." | 4.88 | Evaluation of harm in the pharmacotherapy of irritable bowel syndrome. ( Chong, K; Kim, S; Lembo, A; Pimentel, M; Shah, E, 2012) |
| " The goal of this review is to discern IBS treatment gaps and identify opportunities for improving its management in the primary care setting, as well as describe the most current clinical experience with alosetron, a targeted treatment for severe diarrhea-predominant IBS (IBS-D) in women." | 4.87 | Alosetron for severe diarrhea-predominant irritable bowel syndrome: improving patient outcomes. ( Bleser, S, 2011) |
| " Reports of ischaemic colitis led to restricted use of the approved drug, alosetron." | 4.84 | Is there an experimental basis for the development of ischaemic colitis as a result of 5-HT3 antagonist treatment? ( Camilleri, M, 2007) |
| "Ischemic colitis and serious complications of constipation have been reported in association with the use of alosetron, which is approved for women with severe diarrhea-predominant IBS who have failed conventional therapies." | 4.83 | Incidence of ischemic colitis and serious complications of constipation among patients using alosetron: systematic review of clinical trials and post-marketing surveillance data. ( Chang, L; Chey, WD; Harris, L; Olden, K; Schoenfeld, P; Surawicz, C, 2006) |
| ", 2D6 and 2C19), and the effects of genetic polymorphisms in the promoter of the serotonin transporter protein, which influence the response to alosetron in patients with diarrhea-predominant irritable bowel syndrome." | 4.82 | Pharmacogenomics and functional gastrointestinal disorders. ( Camilleri, M, 2005) |
| "This article evaluates the characteristics and treatment patterns of female patients with severe diarrhea-predominant irritable bowel syndrome (IBS-D) who were treated with alosetron under a risk management program." | 3.78 | Evaluation of treatment continuation with alosetron by IBS-D severity criteria. ( Chuang, E; Nicandro, JP; Shin, P, 2012) |
| " The present study examines the binding profile of platelet SERT in healthy volunteers as well as in patients with diarrhea-predominant irritable bowel syndrome (D-IBS), both before and after treatment with the 5-HT(3) receptor antagonist alosetron." | 3.72 | Platelet serotonin transporter in patients with diarrhea-predominant irritable bowel syndrome both before and after treatment with alosetron. ( Baroni, S; Bellini, M; Betti, L; Blandizzi, C; Colucci, R; Costa, F; Del Tacca, M; Giannaccini, G; Marazziti, D; Marchi, S; Mumolo, MG; Rappelli, L; Stasi, C, 2003) |
| "A 5-HT3 antagonist, alosetron, significantly retards small intestinal and colonic transit in diarrhea-predominant IBS patients, with significantly greater female to male responsiveness." | 3.71 | Gender-related differences in slowing colonic transit by a 5-HT3 antagonist in subjects with diarrhea-predominant irritable bowel syndrome. ( Burton, D; Camilleri, M; McKinzie, S; Pardi, DS; Thomforde, GM; Viramontes, BE, 2001) |
| "Alosetron-treated patients showed improvements in bowel functions compared to placebo-treated patients." | 2.70 | Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome. ( Bagby, B; Carter, E; Decker, C; Gordon, S; Jhingran, P; Lembo, T; Wright, RA, 2001) |
| "In 27 patients with carcinoid diarrhoea, symptoms were recorded daily and gastrointestinal transit was measured by scintigraphy in a three dose (0." | 2.69 | Medium-term effects of a new 5HT3 antagonist, alosetron, in patients with carcinoid diarrhoea. ( Burton, DD; Camilleri, M; Forstrom, LA; Pitot, HC; Rubin, J; Saslow, SB; Scolapio, JS; Thomforde, GM; Zinsmeister, AR, 1998) |
| "Irritable bowel syndrome is categorized into one of three main categories: IBS with diarrhea, IBS with constipation, and IBS with mixed bowel habits." | 2.53 | Emerging treatments in neurogastroenterology: eluxadoline - a new therapeutic option for diarrhea-predominant IBS. ( Lacy, BE, 2016) |
| "Alosetron treatment improved HRQOL scores for all domains (p < ." | 1.51 | Alosetron versus traditional pharmacotherapy in clinical practice: effects on resource use, health-related quality of life, safety and symptom improvement in women with severe diarrhea-predominant irritable bowel syndrome. ( Chey, WD; Chuang, E; Earnest, DL; Olden, KW; Paul Nicandro, J; Shringarpure, R, 2019) |
| " Initial use was widespread, but infrequent serious adverse events of ischemic colitis and severe constipation-related complications prompted alosetron's voluntary withdrawal from the US market in November 2000." | 1.36 | Alosetron for severe diarrhea-predominant irritable bowel syndrome: safety and efficacy in perspective. ( Lewis, JH, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (5.13) | 18.2507 |
| 2000's | 23 (58.97) | 29.6817 |
| 2010's | 13 (33.33) | 24.3611 |
| 2020's | 1 (2.56) | 2.80 |
| Authors | Studies |
|---|---|
| Brenner, DM | 1 |
| Sayuk, GS | 1 |
| Olden, KW | 2 |
| Chey, WD | 3 |
| Shringarpure, R | 2 |
| Paul Nicandro, J | 1 |
| Chuang, E | 3 |
| Earnest, DL | 2 |
| Nee, J | 1 |
| Zakari, M | 1 |
| Lembo, AJ | 2 |
| Cash, BD | 1 |
| Lacy, BE | 3 |
| Rao, T | 1 |
| Moreau, JC | 1 |
| Talley, NJ | 1 |
| Lewis, JH | 1 |
| Bleser, S | 1 |
| Mönnikes, H | 1 |
| Nicandro, JP | 2 |
| Shin, P | 1 |
| Shah, E | 1 |
| Kim, S | 1 |
| Chong, K | 1 |
| Lembo, A | 2 |
| Pimentel, M | 2 |
| Kim, SE | 1 |
| Kubomoto, S | 1 |
| Chua, K | 1 |
| Amichai, MM | 1 |
| Cremonini, F | 2 |
| Atkinson, V | 1 |
| Camilleri, M | 9 |
| Atanasova, E | 1 |
| Carlson, PJ | 1 |
| Ahmad, U | 1 |
| Kim, HJ | 1 |
| Viramontes, BE | 2 |
| McKinzie, S | 2 |
| Urrutia, R | 1 |
| Olden, K | 2 |
| DeGarmo, RG | 1 |
| Jhingran, P | 2 |
| Bagby, B | 2 |
| Decker, C | 2 |
| Markowitz, M | 1 |
| Carter, E | 2 |
| Bobbitt, W | 1 |
| Dahdul, A | 1 |
| DeCastro, E | 1 |
| Gringeri, L | 1 |
| Johanson, J | 1 |
| Levinson, L | 1 |
| Mula, G | 1 |
| Poleynard, G | 1 |
| Stoltz, RR | 1 |
| Truesdale, R | 1 |
| Young, D | 1 |
| Simrén, M | 1 |
| Simms, L | 1 |
| D'Souza, D | 1 |
| Abrahamsson, H | 1 |
| Björnsson, ES | 1 |
| Shen, B | 2 |
| Soffer, EE | 1 |
| Delgado-Aros, S | 1 |
| Ladabaum, U | 1 |
| Bellini, M | 1 |
| Rappelli, L | 1 |
| Blandizzi, C | 1 |
| Costa, F | 1 |
| Stasi, C | 1 |
| Colucci, R | 1 |
| Giannaccini, G | 1 |
| Marazziti, D | 1 |
| Betti, L | 1 |
| Baroni, S | 1 |
| Mumolo, MG | 1 |
| Marchi, S | 1 |
| Del Tacca, M | 1 |
| Ameen, VZ | 3 |
| Gordon, SL | 1 |
| Heath, AT | 3 |
| Carter, EG | 4 |
| Chey, WY | 2 |
| Dukes, GE | 4 |
| Northcutt, A | 1 |
| Chang, L | 2 |
| McSorley, DJ | 1 |
| Mayer, EA | 3 |
| Kawano, K | 1 |
| Mori, T | 1 |
| Fu, L | 1 |
| Ito, T | 1 |
| Niisato, T | 1 |
| Yoshida, S | 1 |
| Shiokawa, S | 1 |
| Sato, Y | 1 |
| Murakami, H | 1 |
| Shishikura, T | 1 |
| Harris, L | 1 |
| Surawicz, C | 1 |
| Schoenfeld, P | 1 |
| Mearin, F | 1 |
| Krause, R | 1 |
| Ameen, V | 1 |
| Gordon, SH | 1 |
| West, M | 1 |
| Perschy, T | 1 |
| Andresen, V | 1 |
| Montori, VM | 1 |
| Keller, J | 1 |
| West, CP | 1 |
| Layer, P | 1 |
| Saslow, SB | 1 |
| Scolapio, JS | 1 |
| Forstrom, LA | 1 |
| Thomforde, GM | 2 |
| Burton, DD | 1 |
| Rubin, J | 1 |
| Pitot, HC | 1 |
| Zinsmeister, AR | 1 |
| Drossman, DA | 1 |
| Heath, A | 2 |
| McSorley, D | 3 |
| Kong, S | 2 |
| Mangel, AW | 2 |
| Northcutt, AR | 3 |
| Watson, ME | 1 |
| Lacey, L | 1 |
| Hahn, B | 1 |
| Soffer, E | 1 |
| Mangel, AM | 1 |
| Lembo, T | 1 |
| Wright, RA | 1 |
| Gordon, S | 1 |
| Pardi, DS | 1 |
| Burton, D | 1 |
| Delvaux, M | 1 |
| Frexinos, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effects of Rifaximin on Visceral Hypersensitivity in Irritable Bowel Syndrome[NCT03462966] | Phase 2 | 4 participants (Actual) | Interventional | 2018-07-01 | Terminated (stopped due to recruitment challenges) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Association of urgency symptom and rectal sensitivity will be evaluated by the mean change in the balloon pressure (measured in mmHg) that leads to first urge sensation to defecate, evaluated based on the visual analogue scale defined in the primary outcome measure. (NCT03462966)
Timeframe: After completing 14-day course of rifaximin.
| Intervention | Millimetre of mercury (Mean) |
|---|---|
| Therapeutic | 106 |
A 100-cubic centimeter visual analogue scale with verbal descriptors (0=no sensation, 20=first sensation, 40=first sense of urge, 60=normal urge to defecate, 80=severe urge to defecate, and 100=discomfort/pain) will be used to score evoked sensations. (NCT03462966)
Timeframe: After completing 14-day course of rifaximin.
| Intervention | volume cubic centimeter (Mean) |
|---|---|
| Therapeutic | 37.5 |
"Normalization of lactulose breath test as a potential predictor of improvement of rectal hypersensitivity will be evaluated by comparing lactulose breath test results pre- and post-treatment.~Normalization of lactulose breath test defined as rise of hydrogen <20 Parts per million within 90 minutes of lactulose ingestion.~patients with positive" (NCT03462966)
Timeframe: After completing 14-day course of rifaximin
| Intervention | Participants (Count of Participants) |
|---|---|
| Therapeutic | 2 |
16 reviews available for alosetron and Diarrhea
| Article | Year |
|---|---|
Current US Food and Drug Administration-Approved Pharmacologic Therapies for the Treatment of Irritable Bowel Syndrome with Diarrhea.
Topics: Adult; Carbolines; Diarrhea; Female; Gastrointestinal Agents; Humans; Imidazoles; Irritable Bowel Sy | 2020 |
Current and emerging drug options in the treatment of diarrhea predominant irritable bowel syndrome.
Topics: Antidepressive Agents, Tricyclic; Antidiarrheals; Carbolines; Diarrhea; Gastrointestinal Agents; Hum | 2015 |
Rifaximin and eluxadoline - newly approved treatments for diarrhea-predominant irritable bowel syndrome: what is their role in clinical practice alongside alosetron?
Topics: Abdominal Pain; Anti-Bacterial Agents; Carbolines; Diarrhea; Gastrointestinal Agents; Humans; Imidaz | 2016 |
Emerging treatments in neurogastroenterology: eluxadoline - a new therapeutic option for diarrhea-predominant IBS.
Topics: Antidiarrheals; Carbolines; Diarrhea; Gastrointestinal Agents; Humans; Imidazoles; Irritable Bowel S | 2016 |
Diarrhea-predominant irritable bowel syndrome: Diagnosis, etiology, and new treatment considerations.
Topics: Carbolines; Diarrhea; Disease Management; Humans; Imidazoles; Irritable Bowel Syndrome; Parasympatho | 2016 |
Alosetron for severe diarrhea-predominant irritable bowel syndrome: improving patient outcomes.
Topics: Carbolines; Cost of Illness; Diarrhea; Female; Gastrointestinal Agents; Humans; Irritable Bowel Synd | 2011 |
Quality of life in patients with irritable bowel syndrome.
Topics: Aged; Carbolines; Constipation; Diarrhea; Female; Gastrointestinal Agents; Health Status; Humans; Ir | 2011 |
Evaluation of harm in the pharmacotherapy of irritable bowel syndrome.
Topics: Alprostadil; Antidepressive Agents, Tricyclic; Carbolines; Constipation; Diarrhea; Gastrointestinal | 2012 |
Efficacy of alosetron in irritable bowel syndrome: a meta-analysis of randomized controlled trials.
Topics: Carbolines; Colonic Diseases, Functional; Diarrhea; Female; Humans; Male; Randomized Controlled Tria | 2003 |
Pharmacogenomics and functional gastrointestinal disorders.
Topics: Carbolines; Colonic Diseases, Functional; Diarrhea; Dyspepsia; Gastrointestinal Agents; Humans; Mode | 2005 |
Incidence of ischemic colitis and serious complications of constipation among patients using alosetron: systematic review of clinical trials and post-marketing surveillance data.
Topics: Carbolines; Clinical Trials as Topic; Colitis, Ischemic; Constipation; Diarrhea; Female; Gastrointes | 2006 |
Is there an experimental basis for the development of ischaemic colitis as a result of 5-HT3 antagonist treatment?
Topics: Carbolines; Colitis; Diarrhea; Humans; Ischemia; Risk Factors; Serotonin 5-HT3 Receptor Antagonists; | 2007 |
[Drug treatment of irritable bowel syndrome: an unmet need].
Topics: Abdominal Pain; Analgesics; Antidepressive Agents, Tricyclic; Antidiarrheals; Carbolines; Controlled | 2007 |
Effects of 5-hydroxytryptamine (serotonin) type 3 antagonists on symptom relief and constipation in nonconstipated irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials.
Topics: Administration, Oral; Carbazoles; Carbolines; Constipation; Diarrhea; Dose-Response Relationship, Dr | 2008 |
The challenge of irritable bowel syndrome: creating an alliance between patient and physician.
Topics: Abdominal Pain; Antidepressive Agents; Antidiarrheals; Carbolines; Cholinergic Antagonists; Colonic | 2001 |
[Visceral sensitivity and functional bowel disorders: physiopathological role and therapeutic perspectives].
Topics: Abdominal Pain; Animals; Benzyl Compounds; Carbolines; Central Nervous System; Colitis, Ulcerative; | 2001 |
12 trials available for alosetron and Diarrhea
| Article | Year |
|---|---|
Randomised clinical trial: alosetron improves quality of life and reduces restriction of daily activities in women with severe diarrhoea-predominant IBS.
Topics: Activities of Daily Living; Adult; Carbolines; Constipation; Diarrhea; Dose-Response Relationship, D | 2012 |
Patient satisfaction with alosetron for the treatment of women with diarrhea-predominant irritable bowel syndrome.
Topics: Adult; Carbolines; Colonic Diseases, Functional; Diarrhea; Female; Gastrointestinal Agents; Humans; | 2002 |
Lipid-induced colonic hypersensitivity in irritable bowel syndrome: the role of 5-HT3 receptors.
Topics: Adult; Carbolines; Catheterization; Colonic Diseases, Functional; Cross-Over Studies; Diarrhea; Doub | 2003 |
Effect of alosetron on bowel urgency and global symptoms in women with severe, diarrhea-predominant irritable bowel syndrome: analysis of two controlled trials.
Topics: Adult; Carbolines; Constipation; Defecation; Diarrhea; Female; Gastrointestinal Agents; Humans; Irri | 2004 |
Long-term safety and efficacy of alosetron in women with severe diarrhea-predominant irritable bowel syndrome.
Topics: Abdominal Pain; Carbolines; Chronic Disease; Diarrhea; Double-Blind Method; Female; Gastrointestinal | 2004 |
A dose-ranging, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS.
Topics: Abdominal Pain; Adult; Aged; Aged, 80 and over; Carbolines; Diarrhea; Dose-Response Relationship, Dr | 2005 |
A randomized, double-blind, placebo-controlled study to assess efficacy and safety of 0.5 mg and 1 mg alosetron in women with severe diarrhea-predominant IBS.
Topics: Carbolines; Constipation; Diarrhea; Double-Blind Method; Drug Tolerance; Female; Gastrointestinal Ag | 2007 |
Medium-term effects of a new 5HT3 antagonist, alosetron, in patients with carcinoid diarrhoea.
Topics: Adult; Aged; Aged, 80 and over; Carbolines; Carcinoid Tumor; Colon; Diarrhea; Double-Blind Method; D | 1998 |
Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist.
Topics: Abdominal Pain; Adult; Canada; Carbolines; Colonic Diseases, Functional; Diarrhea; Dose-Response Rel | 1999 |
Alosetron improves quality of life in women with diarrhea-predominant irritable bowel syndrome.
Topics: Carbolines; Colonic Diseases, Functional; Diarrhea; Double-Blind Method; Female; Humans; Middle Aged | 2001 |
A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome.
Topics: Administration, Oral; Adult; Aged; Carbolines; Colonic Diseases, Functional; Diarrhea; Drug Administ | 2001 |
Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome.
Topics: Carbolines; Colonic Diseases, Functional; Diarrhea; Female; Humans; Middle Aged; Serotonin Antagonis | 2001 |
11 other studies available for alosetron and Diarrhea
| Article | Year |
|---|---|
Alosetron versus traditional pharmacotherapy in clinical practice: effects on resource use, health-related quality of life, safety and symptom improvement in women with severe diarrhea-predominant irritable bowel syndrome.
Topics: Adult; Aged; Carbolines; Diarrhea; Female; Health Resources; Humans; Imidazoles; Irritable Bowel Syn | 2019 |
Board Review Vignette: Irritable Bowel Syndrome.
Topics: Abdominal Pain; Adult; Anion Exchange Resins; Antidiarrheals; Carbolines; Cholestyramine Resin; Cons | 2016 |
Alosetron for severe diarrhea-predominant irritable bowel syndrome: safety and efficacy in perspective.
Topics: Carbolines; Colitis, Ischemic; Constipation; Diarrhea; Dose-Response Relationship, Drug; Female; Hum | 2010 |
Evaluation of treatment continuation with alosetron by IBS-D severity criteria.
Topics: Adolescent; Adult; Aged; Carbolines; Diarrhea; Fecal Incontinence; Female; Follow-Up Studies; Gastro | 2012 |
"Pre-cebo": an unrecognized issue in the interpretation of adequate relief during irritable bowel syndrome drug trials.
Topics: Adult; Carbolines; Desipramine; Diarrhea; Female; Gastrointestinal Agents; Humans; Irritable Bowel S | 2012 |
Serotonin-transporter polymorphism pharmacogenetics in diarrhea-predominant irritable bowel syndrome.
Topics: Adult; Carbolines; Carrier Proteins; Colon; Colonic Diseases, Functional; Diarrhea; Female; Humans; | 2002 |
Alosetron (Lotronex) is back: should I use it to treat my patients with irritable bowel syndrome?
Topics: Carbolines; Colonic Diseases, Functional; Contraindications; Diarrhea; Gastrointestinal Agents; Huma | 2003 |
Safety, efficacy and costs of pharmacotherapy for functional gastrointestinal disorders: the case of alosetron and its implications.
Topics: Carbolines; Colonic Diseases, Functional; Cost-Benefit Analysis; Diarrhea; Female; Gastrointestinal | 2003 |
Platelet serotonin transporter in patients with diarrhea-predominant irritable bowel syndrome both before and after treatment with alosetron.
Topics: Adult; Aged; Blood Platelets; Carbolines; Carrier Proteins; Diarrhea; Female; Humans; Irritable Bowe | 2003 |
Comparison between partial agonist (ME3412) and antagonist (alosetron) of 5-hydroxytryptamine 3 receptor on gastrointestinal function.
Topics: Animals; Carbolines; Constipation; Diarrhea; Dogs; Gastrointestinal Motility; Gastrointestinal Tract | 2005 |
Gender-related differences in slowing colonic transit by a 5-HT3 antagonist in subjects with diarrhea-predominant irritable bowel syndrome.
Topics: Adult; Carbolines; Colon; Colonic Diseases, Functional; Diarrhea; Female; Gastrointestinal Transit; | 2001 |